tldrdailynews.com logo

FDA Approves Groundbreaking Gene Therapies for Sickle Cell Disease, Revolutionizing Treatment Options

1 min read
Source: FDA.gov
FDA Approves Groundbreaking Gene Therapies for Sickle Cell Disease, Revolutionizing Treatment Options
Photo: FDA.gov
TL;DR

The FDA has approved two groundbreaking gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease (SCD) in patients aged 12 and older. Casgevy is the first FDA-approved therapy to use CRISPR/Cas9 genome editing technology, while Lyfgenia utilizes a lentiviral vector for genetic modification. Both therapies involve modifying the patient's own blood stem cells and delivering them back as a one-time infusion. These treatments aim to increase the production of fetal hemoglobin or introduce a gene-therapy derived hemoglobin to prevent the sickling of red blood cells. The approvals mark a significant advancement in gene therapy and offer hope for individuals with SCD, a rare and debilitating blood disorder.

Topics:businesshealth#casgevy#fda#gene-therapy#health#lyfgenia#sickle-cell-disease
Share this article
  1. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease  FDA.gov
  2. Gene editing could be a game changer for patients with sickle cell disease  CBS Mornings
  3. F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editing  The New York Times
  4. A Sickle Cell Breakthrough Is Here. Now the Hard Part.  Bloomberg
  5. The Download: inside the first CRISPR treatment, and smarter robots  MIT Technology Review

Want the full story? Read the original reporting

Read on FDA.gov